VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
CNMDCONMED Corporation
$32.58$1.0B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCNMDPrice Target
CNMD logo

CONMED Corporation (CNMD) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Hold
Based on 21 analysts

139.4% Below Target

CNMD trades 139.4% below Wall Street's consensus target of $78.00.

Current Price$32.58
Average Target$78.00
Target
Current
Low$61.00
Median$78.00
High$95.00

Analyst Target Range

Forward P/E7.5x
(Value)
PEG Ratio0.21
(Undervalued)
Implied Growth+143.7%
(High Growth)
Analyst Spread43.6%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$32.58
Consensus$78.00
High$95.00
Low$61.00

Consensus Scenario Assumptions

The base valuation assumes CNMD achieves its forward estimates and maintains a stable P/E multiple of 7.5x. This scenario reflects the blended consensus of 21 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 21 published analyst recommendations for CNMD

67% hold / mixed conviction
+17
BearishBullish
Weighted analyst sentiment score based on 21 ratings
ConsensusHold
Coverage21 Analysts
Net Score+17
Bull / Bear33% / 0%
Strong Buy00%
Buy733%
Hold1467%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
733%
Hold
1467%
Sell
00%
Strong Sell
00%
Recommendation Mix33% Buy · 67% Hold · 0% Sell
Buy (7)Hold (14)Sell (0)

CNMD Price Target Analysis

Updated June 21, 2026

As of June 21, 2026, CONMED Corporation (CNMD) has a Wall Street consensus price target of $78.00, based on estimates from 21 covering analysts. With the stock currently trading at $32.58, this represents a potential upside of +139.4%. The company has a market capitalization of $1.00B.

Analyst price targets range from a low of $61.00 to a high of $95.00, representing a 44% spread in expectations. The median target of $78.00 aligns closely with the consensus average.

The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.

From a valuation perspective, CNMD trades at a trailing P/E of 21.6x and forward P/E of 7.5x. The forward PEG ratio of 0.21 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +143.7% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $62.46, with bear and bull scenarios of $39.35 and $82.30 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+45.6%
Industry Consensus
Avg Forward P/E
102.6x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
HOLX logo
HOLXHologic, Inc.
$17.0B$76.01$78.69
+3.5%
Hold17.2x42
ATRC logo
ATRCAtriCure, Inc.
$1.5B$28.80$51.33
+78.2%
Buy768.0x19
NVCR logo
NVCRNovoCure Limited
$1.6B$14.28$33.00
+131.1%
Buy—15
MMSI logo
MMSIMerit Medical Systems, Inc.
$4.0B$67.22$94.20
+40.1%
Buy16.5x14
LMAT logo
LMATLeMaitre Vascular, Inc.
$2.1B$93.95$127.50
+35.7%
Buy31.3x20
SYK logo
SYKStryker Corporation
$117.9B$307.80$387.46
+25.9%
Buy20.5x51
ZBH logo
ZBHZimmer Biomet Holdings, Inc.
$17.2B$87.97$96.33
+9.5%
Hold10.4x42
BSX logo
BSXBoston Scientific Corporation
$67.3B$45.29$82.90
+83.0%
Buy13.5x44
EW logo
EWEdwards Lifesciences Corporation
$50.4B$87.36$96.55
+10.5%
Buy29.0x48
GMED logo
GMEDGlobus Medical, Inc.
$10.7B$79.23$109.50
+38.2%
Buy16.7x36

CNMD — Frequently Asked Questions

Quick answers to the most common questions about buying CNMD stock.

What is the CNMD stock price target for 2026?

The consensus Wall Street price target for CNMD is $78, representing 139.4% upside from the current price of $32.58. With 21 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is CNMD a buy, sell, or hold?

CNMD has a consensus rating of "Hold" based on 21 Wall Street analysts. The rating breakdown is mixed, with 14 Hold ratings making up the largest segment. The consensus 12-month price target of $78 implies 139.4% upside from current levels.

Is CNMD stock overvalued or undervalued?

With a forward P/E of 7.4639x, CNMD trades at a relatively low valuation. The consensus target of $78 implies 139.4% appreciation, suggesting meaningful undervaluation.

How high can CNMD stock go?

The most bullish Wall Street analyst has a price target of $95 for CNMD, while the most conservative target is $61. The consensus of $78 represents the median expectation. Our quantitative valuation model projects a bull case target of $82 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover CNMD stock?

CNMD is well covered by analysts, with 21 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 14 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the CNMD stock forecast?

The 12-month CNMD stock forecast based on 21 Wall Street analysts shows a consensus price target of $78, with estimates ranging from $61 (bear case) to $95 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $62, with bear/bull scenarios of $39/$82.

What is CNMD's fair value based on fundamentals?

Our quantitative valuation model calculates CNMD's fair value at $62 (base case), with a bear case of $39 and bull case of $82. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.

What is CNMD's forward P/E ratio?

CNMD trades at a forward P/E ratio of 7.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 21.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy CNMD stock?

Wall Street analysts are very optimistic on CNMD, with a "Hold" consensus rating and $78 price target (139.4% upside). 7 of 21 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do CNMD price targets vary so much?

CNMD analyst price targets range from $61 to $95, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $78 consensus represents the middle ground. Our model's $39-$82 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare